Q3 2023 Results - Reimagining Medicine

Company overview Financial review Conclusions Innovation: Pipeline overview Financial performance Cardiovascular Immunology XXB750 - NPR1 agonist NCT05562934 (CXXB750B12201) Hypertension Indication Phase Phase 2b Patients 170 Primary Outcome Measures week 12 Arms Change from baseline in mean 24hr ambulatory systolic blood pressure at Intervention Target Patients Arm 1 experimental: Dose 1 Arm 2 experimental: Dose 2 Arm 3 experimental: Dose 3 Arm 4 experimental: Dose 4 Arm 5 placebo comparator Resistant Hypertension Patients Readout Milestone(s) 2024 Publication TBD Appendix Innovation: Clinical trials Neuroscience Oncology References Abbreviations Other 51 Investor Relations | Q3 2023 Results NOVARTIS | Reimagining Medicine

View entire presentation